IL33 and lung carcinoma: While we identified many important potential regulators of immune evasion and inflammation that were significantly increased or down-regulated in both metastatic forms of prostate and lung cancers, we specifically focused on the “alarmin” IL-33 that is associated with the inflammatory process, immune recognition and functional development of the newly discovered ILC2s.